Onconetix Files S-1 for Resale of 100M Shares; Details Realbotix Deal
Onconetix filed an S-1 registration statement for the resale of up to 100,000,000 shares of common stock by selling stockholders, primarily from a July 2026 Series F private placement. The company also detailed a Share Exchange Agreement to acquire Realbotix LLC, where the seller could own 75-90% of Onconetix's fully diluted shares post-closing, contingent on Net Cash between $12.5M and $20M. Onconetix secured a new $750M equity line of credit and raised $30.2M in Series F financing, with $30M of the commitment fee satisfied by the PIPE investor's Series F investment. The company continues to face substantial doubt about its ability to continue as a going concern, with a cash balance of $5.4M as of August 10, 2026.
Key Highlights
- Filed S-1 for resale of up to 100,000,000 common shares by selling stockholders.
- Shares for resale represent 2,532% of common stock outstanding as of August 10, 2026.
- Entered Share Exchange Agreement to acquire Realbotix LLC.
- Realbotix seller to own 75-90% of Onconetix fully diluted shares post-closing.
- Secured $30.2M in July 2026 Series F financing.
- Entered $750M equity line of credit agreement with PIPE Investor.
- Cash balance of $5.4M as of August 10, 2026.
- Company faces substantial doubt about its ability to continue as a going concern.
Price Impact
More from ONCO